Shionogi strikes research and option deal with BioVersys for antibacterial assets - FirstWord Pharma
  Shionogi puts more than $600M on the table for Swiss biotech's antibiotic program - Fierce Biotech
  Shionogi puts up to $600m behind BioVersys antibiotics - pharmaphorum
  Swiss firm BioVersys signs deal with Shionogi for antibiotics research - SWI swissinfo.ch
  BioVersys Partners with Shionogi for NTM Clinical Candidate Development - TipRanks
  Shionogi files in Japan to expand pediatric use of COVID-19 antiviral - The Pharma Letter
  BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate - The Manila Times
  Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion - Reuters